These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21890201)

  • 1. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia.
    Orlandi EM; Rocca B; Pazzano AS; Ghio S
    Leuk Res; 2012 Jan; 36(1):e4-6. PubMed ID: 21890201
    [No Abstract]   [Full Text] [Related]  

  • 2. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.
    Dumitrescu D; Seck C; ten Freyhaus H; Gerhardt F; Erdmann E; Rosenkranz S
    Eur Respir J; 2011 Jul; 38(1):218-20. PubMed ID: 21719499
    [No Abstract]   [Full Text] [Related]  

  • 3. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia.
    Rasheed W; Flaim B; Seymour JF
    Leuk Res; 2009 Jun; 33(6):861-4. PubMed ID: 18986702
    [No Abstract]   [Full Text] [Related]  

  • 4. Reversible pre-capillary pulmonary hypertension due to dasatinib.
    Buchelli Ramirez HL; Álvarez Álvarez CM; Rodríguez Reguero JJ; García Clemente MM; Casan Clarà P
    Respir Care; 2014 May; 59(5):e77-80. PubMed ID: 24149673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib-induced pulmonary hypertension in chronic myelogenous leukaemia.
    Yun S; Anwer F; Vincelette ND
    BMJ Case Rep; 2014 Apr; 2014():. PubMed ID: 24810451
    [No Abstract]   [Full Text] [Related]  

  • 6. [Reversible pulmonary hypertension as a consequence of dasatinib treatment in a patient with chronic myeloid leukemia and scleroderma].
    Ryczek R; Góra-Tybor J; Betkier-Lipińska K; Cwetsch A
    Pol Merkur Lekarski; 2013 Jun; 34(204):342-4. PubMed ID: 23882932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis.
    de Lavallade H; Punnialingam S; Milojkovic D; Bua M; Khorashad JS; Gabriel IH; Chaidos A; Olavarria E; Goldman JM; Apperley JF; Marin D
    Br J Haematol; 2008 May; 141(5):745-7. PubMed ID: 18331365
    [No Abstract]   [Full Text] [Related]  

  • 9. Double-edged sword of the new cancer therapeutics.
    Force T
    Circulation; 2012 May; 125(17):2057-8. PubMed ID: 22451582
    [No Abstract]   [Full Text] [Related]  

  • 10. [Reversible pulmonary arterial hypertension related to dasatinib in the treatment for chronic myelogenous leukemia: a case report and literature review].
    Liu B; Wang Y; Mi Y; Wang J
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):581-6. PubMed ID: 25052596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversible dasatinib-related pulmonary arterial hypertension diagnosed by noninvasive echocardiography.
    Wang HC; Lee CS; Liu TC
    Kaohsiung J Med Sci; 2015 Mar; 31(3):165-6. PubMed ID: 25744241
    [No Abstract]   [Full Text] [Related]  

  • 12. Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.
    Tyler T
    Ann Pharmacother; 2009 May; 43(5):920-7. PubMed ID: 19336654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dasatinib combined with weekly administration of vincristine as effective therapy in sudden or resistant Ph+ lymphoid blast crisis of chronic myeloid leukaemia.
    Breccia M; Serrao A; Salaroli A; Loglisci G; Zacheo I; Alimena G
    Br J Haematol; 2012 Dec; 159(5):612-3. PubMed ID: 23043319
    [No Abstract]   [Full Text] [Related]  

  • 14. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.
    Luo FR; Yang Z; Camuso A; Smykla R; McGlinchey K; Fager K; Flefleh C; Castaneda S; Inigo I; Kan D; Wen ML; Kramer R; Blackwood-Chirchir A; Lee FY
    Clin Cancer Res; 2006 Dec; 12(23):7180-6. PubMed ID: 17145844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias].
    Cony-Makhoul P; Bergeron A; Corm S; Dubruille V; Rea D; Rigal-Huguet F; Nicolini FE
    Bull Cancer; 2008 Sep; 95(9):805-11. PubMed ID: 18829412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase].
    Vinogradova OIu; Turkina AG; Vorontsova AV; Chelysheva EIu; Gusarova GA; Kuznetsov SV; Goriacheva SR; Sokolova MA; Abakumov EM; Stakhina OV; Domracheva EV; Misiurin AV; Khoroshko ND
    Ter Arkh; 2009; 81(7):41-6. PubMed ID: 19708572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-.
    Sano M; Saotome M; Urushida T; Katoh H; Satoh H; Ohnishi K; Hayashi H
    Intern Med; 2012; 51(17):2337-40. PubMed ID: 22975544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dasatinib. A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia].
    Bjerrum OW; Dufva IH; Stentoft J; Hasselbalch HC
    Ugeskr Laeger; 2008 Jan; 170(5):331-3. PubMed ID: 18252160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events.
    Shayani S
    Ther Drug Monit; 2010 Dec; 32(6):680-7. PubMed ID: 20864900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.
    Sillaber C; Herrmann H; Bennett K; Rix U; Baumgartner C; Böhm A; Herndlhofer S; Tschachler E; Superti-Furga G; Jäger U; Valent P
    Eur J Clin Invest; 2009 Dec; 39(12):1098-109. PubMed ID: 19744184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.